{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:10:38Z","timestamp":1774577438407,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bcmd.2019.102369","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T20:04:20Z","timestamp":1571947460000},"page":"102369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease"],"prefix":"10.1016","volume":"80","author":[{"given":"Oyebimpe O.","family":"Adesina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac C.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian V.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen B.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika R.","family":"Narla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward W.","family":"Lipkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanika","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Konkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Kruse-Jarres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2019.102369_bb0005","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.bcmd.2019.102369_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcmd.2019.102369_bb0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2141.2005.05476.x","article-title":"Bone involvement in sickle cell disease","volume":"129","author":"Almeida","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2019.102369_bb0020","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/blood-2015-04-641969","article-title":"Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease","volume":"126","author":"Dalle Carbonare","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.102369_bb0025","first-page":"41","article-title":"Type I collagen as a marker of bone metabolism in sickle cell hemoglobinopathies","volume":"90","author":"Bolarin","year":"1998","journal-title":"J. Natl. Med. Assoc."},{"key":"10.1016\/j.bcmd.2019.102369_bb0030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1556\/APhysiol.97.2010.3.5","article-title":"Osteocalcin and specific markers of bone resorption in sickle cell disease","volume":"97","author":"Bolarin","year":"2010","journal-title":"Acta Physiol. Hung."},{"key":"10.1016\/j.bcmd.2019.102369_bb0035","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.21856","article-title":"Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis","volume":"85","author":"Nur","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2019.102369_bb0040","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","author":"Szulc","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bcmd.2019.102369_bb0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cca.2016.06.036","article-title":"Clinical usefulness of bone turnover marker concentrations in osteoporosis","volume":"467","author":"Morris","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bcmd.2019.102369_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0004563213515190","article-title":"Biochemical markers of bone turnover - uses and limitations","volume":"51","author":"Hlaing","year":"2014","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.bcmd.2019.102369_bb0055","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","article-title":"Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy","volume":"26","author":"Christgau","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.bcmd.2019.102369_bb0060","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"Suppl. 2","key":"10.1016\/j.bcmd.2019.102369_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/nep.13014","article-title":"The use of bone turnover markers in chronic kidney disease-mineral and bone disorders","volume":"22","author":"Chiang","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.bcmd.2019.102369_bb0070","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1373\/clinchem.2016.259085","article-title":"Bone turnover markers in the diagnosis and monitoring of metabolic bone disease","volume":"63","author":"Greenblatt","year":"2017","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bcmd.2019.102369_bb0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.13928","article-title":"Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma","volume":"173","author":"Ting","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2019.102369_bb0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jbo.2017.11.001","article-title":"Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer","volume":"10","author":"Hilton","year":"2018","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.bcmd.2019.102369_bb0085","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/pbc.21147","article-title":"Markers of bone turnover are associated with growth and development in young subjects with sickle cell anemia","volume":"50","author":"Fung","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2019.102369_bb0090","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/bloodadvances.2017005256","article-title":"Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California","volume":"1","author":"Adesina","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.bcmd.2019.102369_bb0095","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jpain.2016.12.016","article-title":"AAPT diagnostic criteria for chronic sickle cell disease pain","volume":"18","author":"Dampier","year":"2017","journal-title":"J. Pain"},{"key":"10.1016\/j.bcmd.2019.102369_bb0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/BPO.0000000000000409","article-title":"Hemoglobin to hematocrit ratio: the strongest predictor of femoral head osteonecrosis in children with sickle cell disease","volume":"36","author":"Worrall","year":"2016","journal-title":"J. Pediatr. Orthop."},{"key":"10.1016\/j.bcmd.2019.102369_bb0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2006.07.001","article-title":"Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes","volume":"21","author":"Kato","year":"2007","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcmd.2019.102369_bb0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bcmd.2019.102369_bb0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03940415","article-title":"Kidney disease among patients with sickle cell disease, hemoglobin SS and SC","volume":"11","author":"Drawz","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcmd.2019.102369_bb0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.13967","article-title":"Predictors of renal function progression in adults with homozygous sickle cell disease","volume":"173","author":"Asnani","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2019.102369_bb0125","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.bcmd.2019.102369_bb0130","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00467-016-3370-0","article-title":"Prevalence of acute kidney injury during pediatric admissions for acute chest syndrome","volume":"31","author":"Lebensburger","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.bcmd.2019.102369_bb0135","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00467-017-3623-6","article-title":"Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis","volume":"32","author":"Baddam","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.bcmd.2019.102369_bb0140","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/ndt\/gfq083","article-title":"Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension","volume":"25","author":"Audard","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcmd.2019.102369_bb0145","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1053\/j.ajkd.2012.04.010","article-title":"Day-to-day variability in spot urine protein-creatinine ratio measurements","volume":"60","author":"Naresh","year":"2012","journal-title":"Am. J. Kidney Dis."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979619303110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979619303110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:35:04Z","timestamp":1761050104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979619303110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"alternative-id":["S1079979619303110"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2019.102369","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2019.102369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102369"}}